SPOTLIGHT: Investors cheer Progen data
Australia's Progen Industries saw its share surge after researchers announced that its experimental liver cancer drug demonstrated statistically significant results. Patients taking PI-88 following the removal of a cancerous tumor went an average of 30 weeks before it grew back, compared to 17 weeks for patients who weren't taking the drug. Release | Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
